Table 1. Clinical characteristics of Crohn’s disease (CD) patients.

	Inactive CD patients (n = 13)	Active CD patients (n = 26)
Gender (women/men)	7/6	20/6
Age (median, extremes)	37 (19–59)	28 (19/60)
Disease activity: Harvey-Bradshaw index (HB) median (extremes)	HB: 1 (0–3)	HB: 10 (5–21); Non-severe: n = 15; HB: 9 (5–10); Severe: n = 11; HB: 14 (13–21)
Disease duration (months) (median, extremes)	108 (17–304)	84 (0.5–276)
Type of Crohn’s disease	Inflammatory: n = 9; Stenotic: n = 4	Inflammatory: n = 22; Stenotic: n = 4
Extension	Only ileal: n = 4; Only colonic: n = 4; Ileocolonic: n = 5	Only ileal: n = 5; Only colonic: n = 10; Ileocolonic: n = 11
Perineal disease (yes/no)	4/9	7/19
Treatment*	No treatment: n = 0; Corticosteroids: n = 7; Azathioprine:n = 3; Methotrexate: n = 1; Anti-TNF mAb**: n = 9	No treatment: n = 11; Corticosteroids: n = 8; Azathioprine: n = 7; Methotrexate: n = 2; Anti-TNF mAb**: n = 5
Previous surgery (ileocolonic resection)*** (yes/no)	2/11	2/24

^*Total is higher than the number of patients as some of them receive combination of medication.

^**mAb: Monoclonal antibody. All patients, except two in the active CD patients group failing adalimumab therapy at the time of inclusion, received infliximab.

^***Except ileocolonic resection no patient had underwent other type of small bowel and/or colonic surgery.